| CAS: | 130209-82-4 | ||||||
| 分子式: | C26H40O5 | ||||||
| 分子量: | 432.59 | ||||||
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||||||||||
| L838242 | MACKLIN | 拉坦前列腺素 | ≥98%(HPLC), oil | 69元/5mg; 215元/25mg; 520元/100mg; 2289元/500mg; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||
储存:-20°C 状态:无色到淡黄色液体 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| L795448 | MACKLIN | 拉坦前列腺素 | 10mM in DMSO | 657元/1ml; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||
储存:-20°C | |||||||||||||||||||||||||||||||||||||||||||||||||||
| L0262 | TCI | Latanoprost | >98.0%(HPLC) | 490元/10MG; 1390元/50MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||
基本信息
技术规格
物性(参考值)
安全信息
相关法规
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| 911174 | J&K | Latanoprost | 96%, 一种前列腺素受体激动剂 | 1045元/5MG; 1767元/10MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||
基本信息
产品描述 Latanoprost是前列腺素F2α的类似物,是前列腺素类选择性FP受体的激动剂。Latanoprost增加葡萄膜巩膜外流,因而减少眼压。 靶点(IC50 & Targe) prostanoid selective FP receptor retinoid X receptor α 体外研究 Latanoprost是AMP激活蛋白激酶的间接激活剂,也是一个选择性PXRα拮抗剂[2]。Latanoprost在体外实验中诱导人类肾癌细胞(HCS)的形态异常和活力减弱、细胞周期阻滞。它还诱导了HCS细胞质膜的异常改变、DNA断裂、超微结构的异常以及Caspase的激活。Latanoprost破坏HCS细胞中MTP、减少脂肪生成、促进脂肪酸氧化、增强脂肪细胞和肌小管的GLUT4的转移和葡萄糖的吸收[2]。 体内研究 Latanoprost是一种用于治疗开角型青光眼和高眼压的临床用药。在两种Ⅱ型糖尿病小鼠模型中,能有效改善其葡萄糖和血脂异常。它能改善葡萄糖耐量。慢性给药可减少血脂、增强白色脂肪组织和骨骼肌中的胰岛素通路。Latanoprost能有效激活AMPK,调节糖尿病小鼠中的血糖血脂代谢相关基因[2]。 细胞实验 Cell lines: 人角膜基质细胞(HCS) Concentrations: 50 mg/l-0.78125 mg/l Incubation Time: 4, 8, 12 h Method: 将HCS细胞接种于24孔板,用含10%的DMEM/F12培养基、置于37℃细胞培养箱进行培养。当细胞长至对数期时,将细胞培养基更换为含latanprost的培养基。按前所述条件继续培养,每4小时观察一次他们的形态变化及生长状态。 (Only for Reference) 动物实验 Animal Models: db/db 或 ob/ob 小鼠 Formulation: 0.5% Tween 80 Dosages: 10 或 40 mg/kg Administration: 腹腔注射 (Only for Reference) 参考文献 [1] Shen JW, et al. Curr Eye Res. 2016, 17:1-8. [2] Wang G, et al. Diabetologia. 2013, 56(12):2702-12. [3] Richard L. Hébert, et al. The journal of biological chemistry. 2 安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| C46666 | Alfa Aesar | Latanoprost | 4396元/25mg; 15890元/100mg; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||
基本信息 Ref# 分子式 分子量 GHS危害和防范说明 Hazard Statements Precautionary Statements 安全信息 危险等级 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| L1167 | Sigma-Aldrich | Latanoprost | ≥98% (HPLC) | 2069.62元/1 MG; 7180.23元/5 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||
产品说明 应用 拉坦前列素已被用于:
包装 1, 5 mg in glass bottle 生化/生理作用 拉坦前列素是一种强效、选择性前列腺素F2 α类似物受体激动剂。它在角膜中被酯酶水解为拉坦前列素酸的生物活性形式。拉坦前列素在降低眼内压(IOP)方面起一定作用,因此它具有治疗青光眼的疗效。 特点和优势 该化合物出现在《受体分类和信号转导手册》的 前列腺素类受体 页面。要浏览其他手册页, 单击此处 。 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Y0002218 | Latanoprost | CRS, European Pharmacopoeia (EP) Reference Standard | 16423.3元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. 包装 Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Y0002189 | Latanoprost for system suitability | European Pharmacopoeia (EP) Reference Standard | 16423.3元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. 包装 Unit quantity: 2 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| PHR1884 | Supelco | Latanoprost | Pharmaceutical Secondary Standard; Certified Reference Material | 8978.77元/50 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards 分析说明 These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 附注 To see an example of a Certificate of Analysis for this material enter LRAB0500 in the Documents slot below. This is an example certificate only and may not be the lot that you receive. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||